Bajaj HealthCare Limited (BAJAJHCARE.NS)
- Previous Close
568.20 - Open
568.20 - Bid --
- Ask --
- Day's Range
566.85 - 582.40 - 52 Week Range
263.30 - 745.00 - Volume
197,855 - Avg. Volume
325,861 - Market Cap (intraday)
18.295B - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-0.81 - Earnings Date May 26, 2025
- Forward Dividend & Yield 1.00 (0.17%)
- Ex-Dividend Date Sep 23, 2024
- 1y Target Est
--
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, anthelmintics, anti-asthmatic, antioxidant, urinary tract infection, anti-histamine, weight reducing, venous disease, antimalarial, vitamin c, disinfectant/ antiseptic, stimulant, lipotropic agents, nootropic, vasoprotective/antihemorrhagic, cardiovascular agents, food supplements, anti-anemic, amino acids, antiasthmatic / bronchodilator, nutritional supplement, and minerals. It provides intermediates, such as guanine, 3-methyl xanthine, bromoethyl theophylline, calcium phosphoryl choline chloride, 4-hydrazinobenzoic acid, ticagrelor acetonide, 4,7-dichloroquinolone, 5-[N-ethyl-N-(2-hydroxyethyl)amino]-2-aminopentane, 2-amino -4-hydroxyacetophenone, 8- chloro theophylline, 8 bromo-3-methyl xanthine, 3-methyl-7-(2-butyn-1-yl)-8-bromo xanthine, (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile, 3 amino 1 adamantanol, N boc -sitagliptin, sitagliptin base, hesperidine, (2,7-dichlori-9H-fluorene), (2-Chloro-1-(2,7- dichlori-9H-fluoren-4-yl)ethanone), (2-(dibutylamino)-1-(2, 7- dichlori-9H-fluoren-4-yl)ethanol), (2-Nitro-4-thiocyanoaniline), 4- (propylthio) benzene -1,2-diamine, methyl [(E)amino(methylsulfanyl)methylidene] carbamate, and (2-phenoxy methane sulphonamide). In addition, the company offers formulations in the form of tablets, capsules, sachets, and vials, as well as impurities. Bajaj HealthCare Limited was incorporated in 1993 and is based in Thane, India.
www.bajajhealth.com1,049
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: BAJAJHCARE.NS
View MorePerformance Overview: BAJAJHCARE.NS
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BAJAJHCARE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BAJAJHCARE.NS
View MoreValuation Measures
Market Cap
18.29B
Enterprise Value
19.77B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.19
Price/Book (mrq)
4.10
Enterprise Value/Revenue
3.79
Enterprise Value/EBITDA
36.59
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.31%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
5.22B
Net Income Avi to Common (ttm)
-6.65M
Diluted EPS (ttm)
-0.81
Balance Sheet and Cash Flow
Total Cash (mrq)
228.4M
Total Debt/Equity (mrq)
46.15%
Levered Free Cash Flow (ttm)
--